ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.61
1.02%
US Tech 100
20,630.00
2.11%
S&P 500
5,946.49
1.77%
US Dollar vs CAD
1.43441
-0.06%
Bitcoin
99,238.82
2.83%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. AMEX

  6. Brooklyn ImmunoTherapeutics Inc (BTX) Share Price

Brooklyn ImmunoTherapeutics Inc

Brooklyn ImmunoTherapeutics Inc (BTX)

AMEX
9.79
0.00
( 0.00% )
Updated: 18:00:00
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
9.79
Bid
-
Ask
-
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Market Cap
52.964M
Previous Close
9.79
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
-
Shares Outstanding
5,410,000
Dividend Yield
-
PE Ratio
-0.12
Earnings Per Share (EPS)
-4.01
Revenue
68k
Net Profit
-21.68M

About Brooklyn ImmunoTherapeutics Inc

Brooklyn ImmunoTherapeutics Inc is a clinical-stage biopharmaceutical company. It is developing IRX-2, a novel hd-IL-2 -based therapy, to treat patients with cancer. IRX-2 delivers hd-IL-2 and other key cytokines to potentially restore immune function in the tumor microenvironment, enabling the immu... Brooklyn ImmunoTherapeutics Inc is a clinical-stage biopharmaceutical company. It is developing IRX-2, a novel hd-IL-2 -based therapy, to treat patients with cancer. IRX-2 delivers hd-IL-2 and other key cytokines to potentially restore immune function in the tumor microenvironment, enabling the immune system to attack cancer cells. Show more

Sector
Pharmaceutical Preparations
Industry
Television Broadcast Station
Website
eternatx.com
Headquarters
Wilmington, Delaware, USA
Founded
2022

Ask ADVFN Intelligence (AI)

BTX Latest News

More News

Brooklyn ImmunoTherapeutics Announces Third Quarter 2021 Financial Results

NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing...

November 09 2021
GlobeNewswire Inc.

Brooklyn ImmunoTherapeutics to Move Stock Exchange Listing to Nasdaq

NEW YORK, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene...

October 14 2021
GlobeNewswire Inc.

Brooklyn ImmunoTherapeutics Reports Inducement Grants

NEW YORK, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene...

September 23 2021
GlobeNewswire Inc.

Brooklyn ImmunoTherapeutics Appoints Roger Sidhu, M.D. as Chief Medical Officer

NEW YORK, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene...

September 22 2021
GlobeNewswire Inc.

Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from September 20, 2021

NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene...

September 21 2021
GlobeNewswire Inc.

Factor Bioscience Celebrates 10th Anniversary with Grand Opening of ISO Class 7 Cleanroom Facility in Cambridge, Massachusetts

Factor Bioscience Celebrates 10th Anniversary with Grand Opening of ISO Class 7 Cleanroom Facility in Cambridge, Massachusetts PR Newswire CAMBRIDGE, Mass., Sept. 15, 2021 CAMBRIDGE, Mass., Sept...

September 15 2021
PR Newswire (US)

Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call on Monday, September 20, 2021, at 4:30 PM ET

BROOKLYN, N.Y., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine...

September 13 2021
GlobeNewswire Inc.

Brooklyn ImmunoTherapeutics to Participate in Grand Opening of Cambridge-Based mRNA Cleanroom Facility Shared with Factor Bioscience

NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene...

September 09 2021
GlobeNewswire Inc.

Brooklyn ImmunoTherapeutics Announces Adjournment of Annual Meeting of Stockholders Due to Lack of Quorum

BROOKLYN, N.Y., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and...

August 20 2021
GlobeNewswire Inc.

Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from August 19, 2021

NEW YORK, Aug. 20, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene...

August 20 2021
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

BTX - Frequently Asked Questions (FAQ)

What is the current Brooklyn ImmunoTherapeut... share price?
The current share price of Brooklyn ImmunoTherapeut... is US$ 9.79
How many Brooklyn ImmunoTherapeut... shares are in issue?
Brooklyn ImmunoTherapeut... has 5,410,000 shares in issue
What is the market cap of Brooklyn ImmunoTherapeut...?
The market capitalisation of Brooklyn ImmunoTherapeut... is USD 52.96M
What is the 1 year trading range for Brooklyn ImmunoTherapeut... share price?
Brooklyn ImmunoTherapeut... has traded in the range of US$ 0.00 to US$ 0.00 during the past year
What is the PE ratio of Brooklyn ImmunoTherapeut...?
The price to earnings ratio of Brooklyn ImmunoTherapeut... is -0.12
What is the cash to sales ratio of Brooklyn ImmunoTherapeut...?
The cash to sales ratio of Brooklyn ImmunoTherapeut... is 38.1
What is the reporting currency for Brooklyn ImmunoTherapeut...?
Brooklyn ImmunoTherapeut... reports financial results in USD
What is the latest annual turnover for Brooklyn ImmunoTherapeut...?
The latest annual turnover of Brooklyn ImmunoTherapeut... is USD 68k
What is the latest annual profit for Brooklyn ImmunoTherapeut...?
The latest annual profit of Brooklyn ImmunoTherapeut... is USD -21.68M
What is the registered address of Brooklyn ImmunoTherapeut...?
The registered address for Brooklyn ImmunoTherapeut... is 1209 ORANGE STREET, NEW CASTLE, WILMINGTON, DELAWARE, 19801
What is the Brooklyn ImmunoTherapeut... website address?
The website address for Brooklyn ImmunoTherapeut... is eternatx.com
Which industry sector does Brooklyn ImmunoTherapeut... operate in?
Brooklyn ImmunoTherapeut... operates in the TELEVISION BROADCAST STATION sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
UVIX2x Long VIX Futures ETF
US$ 31.40
(772.22%)
1.29M
MITQMoving iMage Technologies Inc
US$ 1.36
(88.86%)
53.95M
MPUMega Matrix Inc
US$ 1.38
(20.00%)
80.2k
OSTXOS Therapies Incorporated
US$ 4.88
(17.31%)
16.03M
ROLRHigh Roller Technologies Inc
US$ 5.90
(17.30%)
19.76k
AZTRAzitra Inc
US$ 0.2509
(-40.43%)
2.56M
TOVXTheriva Biologics Inc
US$ 1.55
(-18.85%)
136.59k
MTNBMatinas Biopharma Holdings Inc
US$ 0.599
(-14.43%)
306.53k
BNDSInfrastructure Capital Bond Income ETF
 50.27
(-13.04%)
7.11k
VTAKCatheter Precision Inc
US$ 0.4211
(-10.93%)
3.84M
MITQMoving iMage Technologies Inc
US$ 1.36
(88.86%)
53.95M
SOXLDirexion Daily Semiconductor Bull 3X Shares
US$ 30.20
(7.40%)
23.24M
MSTUT Rex 2X Long MSTR Daily Target ETF
US$ 10.89
(8.90%)
17.69M
OSTXOS Therapies Incorporated
US$ 4.88
(17.31%)
16.03M
XLFFinancial Select Sector
US$ 49.32
(2.22%)
15.61M

Discussion

View Full Feed
TexasMarvL TexasMarvL 4 minutes ago
Fresh water can probably be added to this list. 

BTW, the last presentation by Keith Neumeyer about silver he mentioned that Nuclear power will require a lot of Silver.  

I think the quote was that 80% of the core rods are Silver.  I'm not invested in First Majestic, bu
FFMGF
JoeForkeyBolo JoeForkeyBolo 4 minutes ago
BIOTECH TV Interview with CEO John Jacobs

https://www.biotechtv.com/post/novavax-january-14-2025 SF Healthcare Week: After striking a transformational deal with Sanofi, Novavax is ramping up its vaccine pipeline
NVAX
manfromjax manfromjax 5 minutes ago
Hard to carry on with dignity when you own NLST.
Especially on a day like today!
Just thankfully everything else that I own is blasting off with dignity.
NLST
NoMoDo NoMoDo 5 minutes ago
20mil just sold... GTSM contemplating whether to step aside... another 5mil....
HMBL
TenKay TenKay 5 minutes ago
They had a 90 day grace period built into the agreement. Why would they not use it?
HMBL
Pittkid Pittkid 5 minutes ago
Where's the naysayers this morning!
HMBL
DoYourOwnDD DoYourOwnDD 5 minutes ago
Two important transactions are set to take place today (20 days after DEF 14C issued):
- HUMBL will pay $4,000,000 of the purchase price through the issuance of 10,000,000,000 common share to Ybyrá ($0.0004 per share)
- The transfer of the HUMBL assets to WSCG

What will
HMBL
XMaster2023 XMaster2023 5 minutes ago
Especially when you believe there is a treatment that could have extended his life. The current SOC treatment of chemotherapy and radiation is and was almost useless. He smoked for years and then stopped about 2-3 years ago.
NWBO
pinkslipjunkie pinkslipjunkie 5 minutes ago
Not finding anything saying it has though.
AFFU
Hardazoak Hardazoak 5 minutes ago
Company does not need to do anything. Stop with the lies doe.
AABB
MightyX MightyX 6 minutes ago
A.I. made this scare-tactic culture y’all feed-on obsolete.
TPTW
TheFinalCD TheFinalCD 6 minutes ago
found my answer: When a company is acquired, call options on that company's stock typically become worthless, as trading in the options ceases upon the acquisition completion, and any out-of-the-money options will expire with no value; however, the acquiring company may choose to buy out the options
Snelly Snelly 6 minutes ago
Appreciate the update Vulcan!
CLHI
firebag1 firebag1 6 minutes ago
after the bell would be absolutely perfect!!!!!!!!!!!!!!!!!!!!!!!!
HMBL
johnnytrader33 johnnytrader33 6 minutes ago
to advise any potential investor of this SCAM.......and we aint going nowhere. Deal with it.
TSOI
Jetmek_03052 Jetmek_03052 6 minutes ago
Indeed.

This paragraph from the "update" is particularly suspect:

Given the bold guidance the quarterly breakdown has been surgically developed, with milestones quarter to quarter, leveraging the step-by step approach which the Company utilized successfully in its previ
DBMM
DiscoverGold DiscoverGold 6 minutes ago
S&P 500 Technical Analysis
By: Christopher Lewis | January 15, 2025

• The S&P 500 has reached the 50 day EMA as the opening bell approaches and I think at this point in time, it’s likely that we could go looking to the 6,000 level. Breaking above the 6,000 level opens up t
Stevenvegas Stevenvegas 7 minutes ago
added 2.60
BAER
investisseur101 investisseur101 7 minutes ago
We see the same thing i also see 0.0017+
HMBL
TheFinalCD TheFinalCD 7 minutes ago
😁
stockinspector stockinspector 7 minutes ago
Then you don't understand that BOTH parties decide if they will settle. Otherwise the case continues.
Could be as simple as a schedule interference with a business deal appointment and therefore deemed appropriate.
Or the law team may have suggested that Ken pursue settlement rather th
WDLF
getmoreshares getmoreshares 7 minutes ago
EXPERT MARKET- downgraded
STAL

Your Recent History

AMEX
BTX
Brooklyn ImmunoTherapeut...
BIT
UC80LC
Unicredit Bank
CXIO
LDOUSD
Lido DAO Token
BIT
S32553
Societe Generale Effekten
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads